CLS Hosts Congressional Briefing On Restoring Full Tax Expensing for R&D Investments
Back
Today we hosted a Congressional briefing on the urgent need to restore full tax expensing for research and development investments. CLS’s Brent Fisk moderated a panel of emerging biotech leaders to brief Congressional staff on how this tax policy failure is hurting innovation. CLS worked with our partners at Biocom California, BioNJ, HealthCare Institute of New Jersey (HINJ), Life Sciences Pennsylvania, MassBio, MichBio, NC Life Sciences Organization, and NewYorkBIO to drive urgency on this issue.